1.
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
2.
3.
4.
5.
6.
Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands